Drugs / NCR201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06978920 | Jun 2025 → Jul 2026 overdue | Parkinson disease | Nuwacell Biotechnologies Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Hopstem Biotechnology Inc. | Results 2026【五月精选】领域最新进展 hopstem.com ↗
据公布的 首例受试者术后3个月随访数据 ，患者在 运动功能、疾病严重程度及生活质量 等多项核心通用指标上均观察到显著改善，且整体安全性与耐受性良好。 |
| 2026-05-28 | Nuwacell Biotechnologies Co., Ltd. | Results 逆转帕金森！中山医院首例iPSC疗法取得关键突破 nuwacell.com ↗ |
| 2025-10-24 | Nuwacell Biotechnologies Co., Ltd. | Results 中盛溯源荣登“2025中国医药创新种子企业100强” nuwacell.com ↗
治疗3个月即实现全球首例功能性治愈；治疗9个月后，多名患者“关期”消失，中脑多巴胺功能 PET-DAT信号新增最高达 400％以上，口服多巴胺剂量最高下降 38.6％，多项数据均优于Bayer-BlueRock同类产品历史数据。 |
| 2025-09-29 | Nuwacell Biotechnologies Co., Ltd. | Results 全球首例！帕金森病实现功能性治愈，三个月改写生命！ nuwacell.com ↗ |
| 2025-04-28 | Nuwacell Biotechnologies Co., Ltd. | Regulatory 中盛溯源迭代升级帕金森病iPSC疗法IND获批！突破性产品引领行业新风向！ nuwacell.com ↗
近日，国家药监局药品审评中心（CDE）官网公示，中盛溯源的通用高效iDAP细胞药物"NCR201注射液"获批临床，用于治疗帕金森病。 |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Hopstem Biotechnology Inc. | 2026【五月精选】领域最新进展 hopstem.com ↗ |
| 2026-05-28 | Nuwacell Biotechnologies Co., Ltd. | 逆转帕金森！中山医院首例iPSC疗法取得关键突破 nuwacell.com ↗ |
| 2026-01-06 | Nuwacell Biotechnologies Co., Ltd. | 顶尖医院集结！NCR201 Ⅱ 期临床启动会圆满落幕，帕金森病或将迎来「治愈时代」 nuwacell.com ↗ |
| 2025-10-24 | Nuwacell Biotechnologies Co., Ltd. | 中盛溯源荣登“2025中国医药创新种子企业100强” nuwacell.com ↗ |
| 2025-09-29 | Nuwacell Biotechnologies Co., Ltd. | 全球首例！帕金森病实现功能性治愈，三个月改写生命！ nuwacell.com ↗ |
| 2025-04-28 | Nuwacell Biotechnologies Co., Ltd. | 中盛溯源迭代升级帕金森病iPSC疗法IND获批！突破性产品引领行业新风向！ nuwacell.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCR201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06978920 ↗ |
| Modality | Cell therapy | “Human Induced Pluripotent Stem Cell Derived Dopaminergic Progenitor Cells (NCR201) Injection” NCT06978920 ↗ |
| Route | Other | “Bilateral implantation” NCT06978920 ↗ |